ADVERTISEMENT
Press release content from KISSPR. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from KISSPR
Press release content from KISSPR. The AP news staff was not involved in its creation.

TOP RANKED ROSEN LAW FIRM Encourages Enochian BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ENOB

July 31, 2022 GMT
TOP RANKED ROSEN LAW FIRM Encourages Enochian BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ENOB
TOP RANKED ROSEN LAW FIRM Encourages Enochian BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ENOB
TOP RANKED ROSEN LAW FIRM Encourages Enochian BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ENOB
TOP RANKED ROSEN LAW FIRM Encourages Enochian BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ENOB
TOP RANKED ROSEN LAW FIRM Encourages Enochian BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ENOB

07/30/2022, Vancouver Canada · V6E 4A6 // KISS PR Brand Story PressWire //

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Enochian BioSciences, Inc. (NASDAQ: ENOB) between September 24, 2020 and May 31, 2022, both dates inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than September 26, 2022.

SO WHAT: If you purchased Enochian BioSciences securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Enochian BioSciences class action, go to https://rosenlegal.com/submit-form/?case_id=6517 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 26, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

ADVERTISEMENT

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Serhat Gumrukçu, the inventor and co-founder of Enochian BioSciences, was not a licensed doctor and had no verifiable degrees beyond high school; (2) accordingly, the scientific and technological underpinnings of Enochian BioSciences’ product pipeline, purportedly invented by Gumrukçu, were dubious at best; (3) accordingly, the defendants had significantly overstated the commercial prospects for the Company’s product pipeline; (4) Enochian BioSciences’ senior leadership knew Gumrukçuhad a criminal history that included fraud; (5) accordingly, Enochian BioSciences’ reliance on Gumrukçu, and its consulting and licensing agreements with G-Tech Bio, LLC and Seraph Research Institute (“SRI”), both of which are controlled by Gumrukçu, subjected the Company to a heightened risk of reputational and financial harm, as well as threatened the integrity of the Company’s scientific findings; and (6) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

ADVERTISEMENT

To join the Enochian BioSciences class action, go to https://rosenlegal.com/submit-form/?case_id=6517 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

ADVERTISEMENT

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/132325



Source: Newsfile Corp.



Release ID: 335247

Original Source of the original story >> TOP RANKED ROSEN LAW FIRM Encourages Enochian BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ENOB


This content is published on behalf of the above source. Please contact them directly for any concern related to the above.